Popular COVID Drug Remdesivir to cause adverse effects, flagged by IPC
Covid -19 treatment has been challenging since 2020, new drugs are evaluated to control the novel corona virus. Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with in vitro inhibitory activity against SARS-CoV-1 was a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro, however its safety is yet to be...
Covid -19 treatment has been challenging since 2020, new drugs are evaluated to control the novel corona virus. Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with in vitro inhibitory activity against SARS-CoV-1 was a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro, however its safety is yet to be evaluated.
The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of December, has revealed that popular Covid-19 drug Remdesivir is associated with Adverse Drug Reactions (ADRs) named Sinus Bradycardia.
This came after preliminary analysis of Adverse Drug Reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database
with the gathered data IPC cautions health care professionals to closely monitor the ADRs of the drug for further safety.,
For more information check out the full story on the link below:
IPC flags adverse reaction linked to popular COVID drug Remdesivir
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd